SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?


To: Anthony Wong who wrote (712)8/29/1998 10:37:00 PM
From: Mick Mørmøny  Read Replies (1) | Respond to of 1722
 
Viagra and the Wealth of Nations

In the end, economics is not about material progress -- it's about the pursuit of happiness.

What popped into your mind when you first read the headlines about Viagra? Well, I thought about that, too. But as a typical, fun-loving economist I also found myself wondering how the Commerce Department would account for the wonder drug in its estimates of the gross domestic product -- and from there wandered into a reverie about the meaning of economic progress.

Government statisticians will, of course, have no difficulty slotting Viagra into their estimates of "nominal" G.D.P., the sum total of all the money spent in the economy. Viagra's contribution will simply be the total amount that people spend on the pills, or, equivalently, the profits earned and wages paid in the drug's manufacture and distribution. What's more, we can be pretty sure that Viagra's numbers, while music to the stockholders' ears, will make very little difference to the national totals. The new drug's spectacular sales are small change in an $8 trillion economy. And besides, most of the spending on this new product will come at the expense of spending on other things -- say, romantic vacations and candlelight dinners.

But nominal G.D.P. doesn't tell us much. Most of the time, the economic number we care about is "real," or inflation-adjusted, G.D.P., which is supposed to measure the purchasing power as opposed to the dollar income of the economy. Basically, nominal G.D.P. is converted into real G.D.P. by dividing it by a price index -- a "deflator" -- that is supposed to measure the average cost of goods and services sold in the economy.

So far, so good. But what happens with the introduction of Viagra, or Propecia, or whatever the next big thing may be? Statisticians can't compare the prices of these drugs with what they were last year because they weren't around last year. So inevitably, estimates of the deflator take account only of the goods that have been around for at least a little while.

So what? Well, this year some men can buy something they wanted pretty badly -- or baldly, in the case of Propecia -- and they can get it at a reasonable price. Last year they couldn't buy what the pills provide at any price, and probably would have gladly spent far more at clinics or in therapy to get lesser results. So surely, in some sense, the nation's purchasing power has increased because of the availability of those pills.

Yet the numbers you see on real G.D.P. don't reflect that increase -- and they never will. Eventually Viagra will be in the index, and as its price falls in the face of competition, the deflator will fall and measured real income will rise. But at no point will the statistics ever capture the big payoff, the one that happened when Viagra became available for $10 a, um, pop.

How could the statisticians get this right? It would have to involve a subjective evaluation: each person would have to be asked, and would have to answer truthfully, the question "How much money would you have spent last year (with your ever-growing bald spot and that other problem) to be as satisfied as you are now?" Averaging over the population, we would come up with a true measure of the change in the cost of living, and we would deflate G.D.P. by that.

In fact, where they can, the statisticians do try to do something more or less along these lines, adjusting the price of automobiles and many other products by imputations for improved quality. But nearly everyone admits that the imputations fall well short of capturing the real improvement in living standards. Officially, the median family in 1996 had only slightly higher real income than it did in 1973; in reality, that median family would be extremely upset if forced to go back to a 1973 standard of living (no VCR, no microwave, no A.T.M.'s).

So what's the moral? Should we smugly assume that the official statistics understate economic progress, that the New Economy is speeding us to a new age of economic bliss? Not so fast. For one thing, it is by no means clear that our age of technological marvels is any more marvelous than the age our parents, grandparents or great-grandparents lived in.

Viagra is only the latest in a long line of medical miracles -- antibiotics, smallpox vaccine, anesthesia -- just as the Internet is only the latest in a line that goes back to the fax machine, the telephone and the telegraph. While the statistics do understate today's true rate of economic progress, they always have.

But there is a deeper point. The value of Viagra is not a dollar-and-cents issue. Rather, it is a psychological question -- what we are really asking is how much better off the drug makes people feel. But isn't that true of economic progress in general? And once you put it that way, you have to wonder whether we are really making that much progress after all.

Consider: According to the official statistics, the median family in 1947 had almost exactly the same purchasing power as the 20th-percentile family -- just a little ways above the poverty line -- of 1996. And the statistics surely understate the true increase in purchasing power. Does that mean that most people in 1947 were poor? Well, they didn't feel poor. Conversely, the 60th percentile in 1996 officially had about the same real income as the 95th percentile in 1947, and again this surely understates the real progress.

Does this mean that most Americans are now upper middle class? They don't feel that way.

In other words, as soon as you try to think seriously about how to measure Viagra's effect on the nation's wealth, you realize what a dubious enterprise such comparisons are. I have nothing against calculating real G.D.P. as accurately as possible; we need that number for all kinds of purposes. But the rather vulgar case of Viagra reminds us that, in the end, economics is not about wealth -- it's about the pursuit of happiness.

The Capitalist
By PAUL KRUGMAN
Sunday, August 23, 1998
The New York Times Magazine



To: Anthony Wong who wrote (712)8/30/1998 2:34:00 AM
From: Anthony Wong  Read Replies (1) | Respond to of 1722
 
Wellcome seeks alliance to keep genes data public
The Sunday Times, August 30 1998

Matthew Lynn

THE Wellcome Trust and America's National Institutes of
Health are trying to link with top drug companies to create
a jointly funded database of human genes.

The project, which is at an early stage but could cost
hundreds of millions of pounds, is being promoted by
James Watson, the Nobel prizewinner and co-discoverer
of DNA in the 1950s. There are fears that recent initiatives
by American companies may result in human genetic codes
being owned by private companies. This might deny
scientists unable to pay big licence fees access and could
thus slow scientific and medical progress.

A huge amount of investment has gone into the Human
Genome Project, a multinational effort to create a public
database of the hundreds of thousands of genes that make
up the human body. Attention is focusing on
polymorphines, known as SNPs, which define the genetic
difference between one person and another.

It is believed SNPs could have big implications for medical
research and the drugs industry. Michael Morgan, chief
executive of the Wellcome Trust Genome Centre, said:
"We are looking to fund an SNPs database that will keep
this in the public domain." It is estimated the database
could cost $400m (œ240m) to create.

Concern has been prompted by the recent change of
direction by Perkin-Elmer, an American company that has
about 90% of the world market in making gene-sequencing
systems. With Craig Venter, an American scientist, it is
trying to patent information on SNPs for private use.

SNPs could prove important in making existing drugs more
useful, as well as providing a platform for the discovery of
new ones. For example, some drugs cause side-effects,
but if simple genetic scans were available, it should be
possible to tell who can take what drugs. The attempt by
Perkin-Elmer and Venter to keep this sequencing data to
themselves is causing concern among scientists and drug
companies.

Advances in genetic sequencing technology are making the
mapping of the human genome much faster, and allowing
scientists to move to the more complex task of mapping
genetic differences between people.

The market for gene sequencing has become more
competitive with the acquisition of Molecular Dynamics by
Amersham Pharmacia Biotech, a joint venture between
Britain's Nycomed Amersham and Pharmacia & Upjohn of
America.

Molecular Dynamics is the main rival to Perkin-Elmer in
the fast-growing market for gene-sequencing equipment.
Unlike Perkin-Elmer, it intends only to supply the system
and has no intention of using the system itself.

sunday-times.co.uk:80/news/pages/Sunday-Times/frontpage.html?2383892